Seroquel XR in the Long Term Treatment of Schizophrenia

Completed

• Conditions: Relapse in Schizophrenia

• Registration Number: NCT01202617
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients

Detailed Description

Not available

Study Timeline

• Study Start: 2010-09
• Study First Submitted: 2010-09-14
• Study First Submitted QC: 2010-09-14
• Study First Posted: 2010-09-16
• Status Verified: 2011-10
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Last Update Submitted: 2011-10-21
• Last Update Posted: 2011-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1606

Inclusion Criteria

• schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion Criteria

• Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of patients remained relapse free after 6 months of treatment	on the 180th day of treatment

Secondary Outcome Measures

Name	Time	Method
connection between relapse and affective symptoms	180th day of treatment

Trial Locations

Locations (1)

Research Site; 🇭🇺 Zalegerszeg, Hungary